Measuring Patient Engagement Hilton Boston Back Bay, Boston

Patient engagement is becoming increasingly embedded in the drug development process, driven by both internal and external stakeholders. Externally, progressively aware and proactive patients are demanding more involvement in decisions involving their treatment, and regulatory pressures from global regulatory agencies are mounting. Internally, drug developers themselves are not only recognising that patient engagement is ‘the right thing to do’, but that it also drives success throughout the drug development process. While transformative progress has been made in engaging patients throughout the pharma value chain, there is work to be done when it comes to measuring, assessing and systematically reporting these efforts to internal and external stakeholders.

Dedicated to measuring the success of patient engagement throughout the drug development lifecycle, the inaugural Measuring Patient Engagement Summit serves as a pivotal platform to collectively build a standardized framework to measure the value of patient engagement and ensure that patient engagement remains a key driver for success in drug development.

Join 70+ Chief Patient Officers, Patient Engagement leaders and Patient Advocacy experts, from esteemed pharmaceutical and biotech companies, such as Novartis, Otsuka, Boehringer Ingelheim, AstraZeneca and many more, to establish a roadmap to quantify the success of your patient engagement work.